InMode Ltd. (INMD) Stock Analysis

Company Overview

InMode Ltd. operates within the healthcare sector specifically as a manufacturer and marketer of medical devices focused on aesthetic medicine. The company designs, develops, and produces minimally invasive aesthetic medical products utilizing proprietary technologies such as radio frequency assisted lipolysis and deep subdermal fractional radiofrequency. These devices are marketed across the United States, Europe, Asia, and other international regions to address diverse aesthetic medical needs. With a market capitalization of $868.01M and annual revenue of $370.50M, InMode Ltd. demonstrates the scale of a mid-to-large cap entity in the medical device industry. The market cap figure of $868.01M reflects significant investor confidence in the commercial viability of its proprietary radio frequency technologies. The annual revenue of $370.50M indicates a substantial operational footprint that supports a workforce of 660 employees globally. These financial figures collectively position the company as a established player capable of sustaining research and development while expanding its product portfolio in the competitive medical device landscape.

Financial Health

The company reported revenue of $370.50M for the trailing twelve months, accompanied by a net income of $93.83M and an EBITDA of $86.08M. The gap between the $370.50M revenue and the $93.83M net income reveals a cost structure where operating expenses and taxes consume approximately 74.7% of total sales, though the high gross margin mitigates this pressure. Free cash flow stands at $39.10M, indicating that the company generates sufficient cash from operations to fund capital expenditures and potentially return value to shareholders or reduce debt. The gross margin of 78.5% suggests that the manufacturing of medical devices involves high value-added components with low cost of goods sold relative to sales price. Operating margin is recorded at 25.0%, while profit margin reaches 25.3%, indicating that the company retains a significant portion of revenue after covering all operating and tax obligations. Total cash holdings of $555.33M vastly exceed total debt of $8.23M, resulting in a debt-to-equity ratio of 1.20, which implies a conservative balance sheet despite the leverage metric appearing elevated due to the specific accounting treatment of cash in the denominator. The current ratio of 9.88 signifies extremely strong short-term liquidity, as current assets are nearly ten times current liabilities. Return on equity is 13.5% and return on assets is 6.9%, metrics that reveal management is effectively utilizing shareholder capital and total assets to generate profits within a capital-intensive environment.

Valuation Assessment

The trailing twelve-month P/E ratio is 9.58, while the forward P/E is 8.95, implying that the market expects earnings to grow in the future to justify the lower forward multiple. The price-to-book ratio of 1.27 indicates that the stock trades at a slight premium over its book value, reflecting intangible assets like proprietary technology that are not fully captured on the balance sheet. The price-to-sales ratio is 2.34, and the EV/EBITDA stands at 3.73, suggesting that valuation multiples are compressed relative to the high growth potential often seen in medical device sectors. The 52-week high is $19.09 and the 52-week low is $12.72, providing a trading range context for the asset. Without a specific current share price provided in the available facts to calculate a precise percentage, the price sits within a range defined by these historical highs and lows, exhibiting the volatility typical of small-to-mid cap biotech and medical device stocks. The beta of 2.19 indicates that the stock price is significantly more volatile than the broader market, moving with greater magnitude than the S&P 500 in response to market fluctuations.

Growth & Income

Revenue growth year-over-year is 6.1%, whereas earnings growth year-over-year is -63.5%, indicating that earnings are currently contracting while revenue expands. This divergence suggests that cost pressures or one-time charges may be impacting net income disproportionately to top-line sales performance. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, effectively reinvesting earnings into growth initiatives rather than paying out cash to shareholders. The absence of a dividend yield of N/A and a payout ratio of 0.0% confirms the capital allocation strategy prioritizes expansion and research over income distribution. The overall growth and income profile is characterized by positive revenue expansion tempered by a significant contraction in earnings, with no current reliance on dividend income for investors.